Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent i...

Full description

Bibliographic Details
Main Authors: Rulan Griesel, Andrew Hill, Graeme Meintjes, Gary Maartens
Format: Article
Language:English
Published: Wellcome 2021-01-01
Series:Wellcome Open Research
Online Access:https://wellcomeopenresearch.org/articles/6-1/v1

Similar Items

Similar Items